AU2005317304B2 - Deacylation of LPS in Gram negative bacteria - Google Patents

Deacylation of LPS in Gram negative bacteria Download PDF

Info

Publication number
AU2005317304B2
AU2005317304B2 AU2005317304A AU2005317304A AU2005317304B2 AU 2005317304 B2 AU2005317304 B2 AU 2005317304B2 AU 2005317304 A AU2005317304 A AU 2005317304A AU 2005317304 A AU2005317304 A AU 2005317304A AU 2005317304 B2 AU2005317304 B2 AU 2005317304B2
Authority
AU
Australia
Prior art keywords
lps
pagl
lipid
bacterium
gram negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005317304A
Other languages
English (en)
Other versions
AU2005317304A1 (en
Inventor
Jeroen Johannes Gerardus Geurtsen
Johannes Petrus Maria Tommassen
Peter Andre Van Der Ley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of AU2005317304A1 publication Critical patent/AU2005317304A1/en
Assigned to DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS reassignment DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS Request for Assignment Assignors: NVI NEDERLANDS VACCININSTITUUT
Application granted granted Critical
Publication of AU2005317304B2 publication Critical patent/AU2005317304B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005317304A 2004-12-17 2005-12-16 Deacylation of LPS in Gram negative bacteria Ceased AU2005317304B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078445 2004-12-17
EP04078445.6 2004-12-17
PCT/NL2005/050081 WO2006065139A2 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Publications (2)

Publication Number Publication Date
AU2005317304A1 AU2005317304A1 (en) 2006-06-22
AU2005317304B2 true AU2005317304B2 (en) 2011-06-23

Family

ID=34928754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005317304A Ceased AU2005317304B2 (en) 2004-12-17 2005-12-16 Deacylation of LPS in Gram negative bacteria

Country Status (15)

Country Link
US (1) US8048433B2 (enExample)
EP (1) EP1828378B1 (enExample)
JP (1) JP5378685B2 (enExample)
CN (1) CN101203605B (enExample)
AU (1) AU2005317304B2 (enExample)
BR (1) BRPI0519923A8 (enExample)
CA (1) CA2590906C (enExample)
DK (1) DK1828378T3 (enExample)
ES (1) ES2493440T3 (enExample)
MX (1) MX2007007288A (enExample)
NO (1) NO340331B1 (enExample)
NZ (1) NZ555889A (enExample)
PL (1) PL1828378T3 (enExample)
PT (1) PT1828378E (enExample)
WO (1) WO2006065139A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681924C (en) * 2007-03-26 2019-12-31 De Staat Der Nederlanden, Vert. Door De Minster Van Vws Improved vaccines against bordetella pertussis based on lps glycosyltransferase mutants
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2015525794A (ja) 2012-08-06 2015-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160120967A1 (en) 2013-06-04 2016-05-05 Petr Gennadievich Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CN104388368B (zh) * 2014-10-30 2017-02-15 四川农业大学 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法
KR102888356B1 (ko) * 2016-01-28 2025-11-19 인트라백 비.브이. 변형된 테트라-아실화된 나이세리아 lps
CN105567620B (zh) * 2016-01-29 2019-03-19 江南大学 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用
CN105695540A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种革兰氏阴性菌胞壁抗原的制备方法
CA3055757A1 (en) * 2017-03-13 2018-09-20 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Bordetella vaccines comprising lps with reduced reactogenicity
US11744884B2 (en) * 2017-05-15 2023-09-05 University Of Maryland, Baltimore Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
AU2018379236B2 (en) * 2017-12-04 2025-02-27 Intravacc B.V. An improved process for producing outer membrane vesicles
WO2021228930A2 (en) * 2020-05-14 2021-11-18 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
EP4208472A1 (en) 2020-09-04 2023-07-12 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650681A5 (en) 1981-08-14 1985-08-15 Dso Pharmachim Whooping cough vaccine
WO1989001976A1 (en) * 1987-09-04 1989-03-09 Amgen Inc. Recombinant dna-derived bordetella toxin subunit analogs
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
HU219819B (hu) * 1992-08-18 2001-08-28 Dimminaco Ag/Sa/Ltd. Izolált polinukleotidok, ezeket tartalmazó Bordetella bronchiseptica törzs, és Bordetella bronchiseptica elleni vakcina
ES2180758T3 (es) * 1995-05-04 2003-02-16 Aventis Pasteur Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
CA2284586C (en) * 1997-04-01 2011-02-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
DK1127137T4 (da) * 1998-11-03 2014-02-10 Nederlanden Staat LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Caroff, M. et al (2001) Journal of Endotoxin Research 7(1): 63-68 *
Parkhill, J. et al (2003) Nature Genetics 35(1): 32-40 & Database Uniprot Accession No: Q7W5H1 & Database Uniprot Accession No: Q7WD07 *

Also Published As

Publication number Publication date
CN101203605A (zh) 2008-06-18
CA2590906C (en) 2017-01-03
JP2008523805A (ja) 2008-07-10
AU2005317304A1 (en) 2006-06-22
US20080274145A1 (en) 2008-11-06
NO340331B1 (no) 2017-04-03
CA2590906A1 (en) 2006-06-22
CN101203605B (zh) 2016-01-27
WO2006065139A2 (en) 2006-06-22
DK1828378T3 (da) 2014-09-01
ES2493440T3 (es) 2014-09-11
PL1828378T3 (pl) 2014-10-31
WO2006065139A3 (en) 2006-10-19
NO20073088L (no) 2007-09-17
US8048433B2 (en) 2011-11-01
MX2007007288A (es) 2008-02-25
EP1828378B1 (en) 2014-06-11
EP1828378A2 (en) 2007-09-05
NZ555889A (en) 2009-07-31
PT1828378E (pt) 2014-10-10
BRPI0519923A8 (pt) 2018-01-23
JP5378685B2 (ja) 2013-12-25
BRPI0519923A2 (pt) 2009-08-11

Similar Documents

Publication Publication Date Title
AU2005317304B2 (en) Deacylation of LPS in Gram negative bacteria
US5770719A (en) Membrane-associated immunogens of mycobacteria
Geurtsen et al. Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JPH10513349A (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
US10414805B2 (en) Gonorrheal MtrE peptides and vaccines
JP2020510726A (ja) 低下した反応源性を有するｌｐｓを含むボルデテラワクチン
Lo et al. Characterization of two lipoproteins in Pasteurella multocida
West et al. Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis
CN106536544B (zh) 艰难梭菌免疫原性组合物
CA2378862C (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
Jurado-Martín et al. Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ
JP7303791B2 (ja) スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
RU2677790C1 (ru) Рекомбинантная плазмидная ДНК pPA-OPRF-ATOX-OPRI, кодирующая синтез гибридного рекомбинантного белка, включающего аминокислотные последовательности белков F и I наружной мембраны и атоксического варианта экзотоксина A Pseudomonas aeruginosa, штамм Escherichia coli PA-OPRF-ATOX-OPRI - продуцент гибридного рекомбинантного белка и способ получения указанного белка
US12403189B2 (en) Immunogenic antigens
Jang et al. Comparative structural and immunological analysis of outer membrane proteins and dermonecrotic toxin in Bordetella bronchiseptica canine isolate
MXPA01008913A (es) Vacuna multicomponente que comprende por lo menos tres antigenos para proteger contra la enfermedad producida por haemophilus influenzae.
KR101713635B1 (ko) 비브리오 패혈증균의 시스테인 단백질 분해효소 도메인 유래 재조합 단백질 및 이의 용도
Geurtsen Improving pertussis vaccines by lipopolysaccharide engineering

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER V

Free format text: FORMER APPLICANT(S): NVI NEDERLANDS VACCININSTITUUT

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired